KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $5.5 million.

  • Novavax's Interest Expenses rose 2941.45% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 4637.2%. This contributed to the annual value of $20.1 million for FY2024, which is 3925.5% up from last year.
  • Latest data reveals that Novavax reported Interest Expenses of $5.5 million as of Q3 2025, which was up 2941.45% from $5.5 million recorded in Q2 2025.
  • Over the past 5 years, Novavax's Interest Expenses peaked at $7.6 million during Q4 2024, and registered a low of $2.9 million during Q3 2023.
  • Moreover, its 5-year median value for Interest Expenses was $4.8 million (2021), whereas its average is $4.9 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first crashed by 4988.77% in 2023, then surged by 8423.61% in 2024.
  • Novavax's Interest Expenses (Quarter) stood at $5.1 million in 2021, then fell by 10.45% to $4.6 million in 2022, then decreased by 10.52% to $4.1 million in 2023, then soared by 84.24% to $7.6 million in 2024, then fell by 27.73% to $5.5 million in 2025.
  • Its Interest Expenses was $5.5 million in Q3 2025, compared to $5.5 million in Q2 2025 and $5.7 million in Q1 2025.